Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR2 | Q969V1 | 1/20 | 0.60 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | NPC1L1 | Q9UHC9 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | OXTR | P30559 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3839355 | 0.84 | MCHR2 (0.61) | MCHR2HSD11B1HPGDNPC1L1 | |
| SCHEMBL4984631 | 0.79 | MCHR2 (0.60) | MCHR2HSD11B1HPGDNPC1L1KMT2A | |
| SCHEMBL762618 | 0.79 | MCHR2 (0.58) | MCHR2HSD11B1NPC1L1OXTR | |
| SCHEMBL3840707 | 0.79 | HSD11B1 (0.57) | MCHR2HSD11B1NPC1L1OXTR | |
| SCHEMBL762613 | 0.78 | MCHR2 (0.57) | MCHR2HSD11B1NPC1L1 | |
| SCHEMBL395086 | 0.78 | HSD11B1 (0.64) | MCHR2HSD11B1NPC1L1OXTR | |
| SCHEMBL738652 | 0.77 | MCHR2 (0.54) | MCHR2HSD11B1NPC1L1KMT2APOLB | |
| SCHEMBL4236501 | 0.76 | MCHR2 (0.55) | MCHR2HSD11B1NPC1L1 | |
| SCHEMBL3841546 | 0.75 | TACR1 (0.55) | HSD11B1HPGDPKMKMT2APOLB | |
| SCHEMBL14112458 | 0.74 | CCR2 (0.43) | MCHR2HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2535329-A2 | Spiro-piperidine derivatives | F. Hoffmann-La Roche AG (CH) | 2012-12-19 | — | — | EP | disclosed |
| EP-2535329-A2 | Spiro-piperidine derivatives | F. Hoffmann-La Roche AG (CH) | 2012-12-19 | — | — | EP | disclosed |
| US-8084609-B2 | Vasopressin receptor (V1a) antagonists, treatment of anxiety and depressive disorders and other diseases | HOFFMAN-LA ROCHE INC. (US) | 2011-12-27 | — | — | US | disclosed |
| US-8084609-B2 | Vasopressin receptor (V1a) antagonists, treatment of anxiety and depressive disorders and other diseases | HOFFMAN-LA ROCHE INC. (US) | 2011-12-27 | — | — | US | disclosed |
| US-8084609-B2 | Vasopressin receptor (V1a) antagonists, treatment of anxiety and depressive disorders and other diseases | HOFFMAN-LA ROCHE INC. (US) | 2011-12-27 | — | — | US | disclosed |
| EP-2097376-A2 | SPIRO-PIPERIDINE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2009-09-09 | — | — | EP | disclosed |
| WO-2008077810-A2 | SPIRO-PIPERIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-07-03 | — | — | WO | disclosed |
| WO-2008077810-A2 | SPIRO-PIPERIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-07-03 | — | — | WO | disclosed |
| US-20080153861-A1 | SPIROPIPERIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-06-26 | — | — | US | disclosed |
| US-20080153862-A1 | SPIROPIPERIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-06-26 | — | — | US | disclosed |
| US-20080153862-A1 | SPIROPIPERIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-06-26 | — | — | US | disclosed |
| US-20080153862-A1 | SPIROPIPERIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-06-26 | — | — | US | disclosed |
| US-20080153861-A1 | SPIROPIPERIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-06-26 | — | — | US | disclosed |
| US-20080153861-A1 | SPIROPIPERIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-06-26 | — | — | US | disclosed |
| US-20080153863-A1 | SPIROPIPERIDINE DERIVATIVES | HOFFMAN-LA ROCHE INC. | 2008-06-26 | — | — | US | disclosed |
| US-20080153863-A1 | SPIROPIPERIDINE DERIVATIVES | HOFFMAN-LA ROCHE INC. | 2008-06-26 | — | — | US | disclosed |
| US-20080153863-A1 | SPIROPIPERIDINE DERIVATIVES | HOFFMAN-LA ROCHE INC. | 2008-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080153863-A1 | SPIROPIPERIDINE DERIVATIVES | AVPR1A, AVPR1B, AVPR2 | MCHR2 325/4885HSD11B1 1341/4885HPGD 1599/4885 |
| US-20080153861-A1 | SPIROPIPERIDINE DERIVATIVES | AVPR1A, AVPR1B, AVPR2 | MCHR2 325/4885HSD11B1 1341/4885HPGD 1599/4885 |
| US-20080153862-A1 | SPIROPIPERIDINE DERIVATIVES | AVPR1A, AVPR1B, AVPR2 | MCHR2 325/4885HSD11B1 1341/4885HPGD 1599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.